Business
Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes
Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today reported positive early pilot performance data for ViraxImmune™, its blood-based test in development for Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome ("ME/CFS") and related post-acute infection syndromes ("PAIS"). In the pilot dataset, ViraxImmune™ demonstrated measurable separation between PAIS patients and healthy controls, achieving 88% specificity and 92% positive predictive value ("PPV") — early pe
About this update from Virax Biolabs Group Limited
[{"type":"text","content":"LONDON, May 26, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today reported positive early pilot performance data for ViraxImmune™, its blood-based test in development for Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome ("ME/CFS") and related post-acute infection syndromes ("PAIS"). In the pilot dataset, ViraxImmune™ demonstrated measurable separation between PAIS patients and healthy controls, achieving 88% specificity and 92% positive predictive value ("PPV") — early performance metrics that Virax believes support continued development and advancement into larger clinical validation.","length":703,"tagName":"p"},{"type":"image","alt":"Logo (PRNewsfoto/Virax BioLabs Group Limited)","displaySize":"","headline":null,"caption":"Logo (PRNewsfoto/Virax BioLabs Group Limited)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":60,"url":"https://media.zenfs.com/en/prnewswire.com/3557d954e9714d423e9a669da95b5821"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6WZEeaOoR.Nx_oMzQzha.w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEwNg--/https://media.zenfs.com/en/prnewswire.com/3557d954e9714d423e9a669da95b5821","width":400,"height":60},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/SApbkc8BAcZZ8_yoIqOgLw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTk2/https://media.zenfs.com/en/prnewswire.com/3557d954e9714d423e9a669da95b5821","width":400,"height":60}},"href":"https://mma.prnewswire.com/media/2730505/Virax_Biolabs_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Based on estimates derived from CDC, the RECOVER Initiative and other peer-reviewed and public-health sources, Virax estimates that up to 21 million adults in the United States may currently be living with Long COVID and related PAIS conditions, with approximately 2.5 million new cases estimated each year. Virax believes this represents a significant potential U.S. testing opportunity in an area where many patients are often assessed through symptoms and exclusion, rather than objective immune biomarkers of the type ViraxImmune™ is being developed to assess.","length":564,"tagName":"p"},{"type":"text","content":"Highlights:","length":11,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In the pilot...